HLA
IKT icon

Hamilton Lane Advisors’s Inhibikase Therapeutics IKT Stock Holding History

Hamilton Lane Advisors’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,802
Closed -$49.8K – 41
2023
Q2 		$49.8K Sell
13,802
-1
-0% -$4 0.02% 50
2023
Q1 		$54.5K Buy
+13,803
New +$57.6K 0.02% 60
2022
Q4 		– Sell
-27,606
Closed -$151K – 72
2022
Q3 		$151K Hold
27,606
– – 0.06% 60
2022
Q2 		$123K Hold
27,606
– – 0.05% 67
2022
Q1 		$245K Buy
+27,606
New +$222K 0.05% 66

Other funds holding IKT

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $401M AUM 14.95% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hamilton Lane Advisors's IKT Position: Q3 2023 in Review

Hamilton Lane Advisors sold out of Inhibikase Therapeutics (IKT) in Q3 2023, closing a stake of 13,802 shares — an estimated $49.8K sold.

Hamilton Lane Advisors first reported a position in IKT in Q1 2022 and held it in 5 quarters. The position peaked at $245K in Q1 2022. 13 funds tracked by Wall St. Rank hold IKT as of Q3 2023.

  • Hamilton Lane Advisors reported no remaining Inhibikase Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Hamilton Lane Advisors sold 13,802 Inhibikase Therapeutics shares in Q3 2023, an estimated $49.8K.
  • Hamilton Lane Advisors first reported a position in Inhibikase Therapeutics in Q1 2022 and held it in 5 quarters.
  • Hamilton Lane Advisors's Inhibikase Therapeutics position peaked at $245K in Q1 2022.
  • 13 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2023.

Based on Hamilton Lane Advisors's 13F filing for Q3 2023, filed 7 Nov 2023.